Examination of Efficacy and Safety of Baricitinib in RA Patients

• Status: Recruiting
• Trial end date: 2025-11-20
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to examine the efficacy and adverse events in the following 3 groups in rheumatoid arthritis patients:

1. Baricitinib treatment for 12 months

2. Biologics treatment for 12 months

3. Tofacitinib treatment for 12 months

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shinshu University
• Treatments: Tofacitinib

Criteria

Inclusion Criteria:

• RA patients

Exclusion Criteria:

• Not RA patients

• RA patients who are allergic to the drugs, refused to do this research, or who are pregnant